Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Cash & Equivalents (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Cash & Equivalents for 13 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 41.55% to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 million, a 41.55% decrease, with the full-year FY2025 number at $1.2 million, down 41.55% from a year prior.
  • Cash & Equivalents was $1.2 million for Q4 2025 at Ekso Bionics Holdings, down from $2.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $49.5 million in Q1 2021 to a low of $1.2 million in Q4 2025.
  • A 5-year average of $19.4 million and a median of $11.6 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: surged 481.72% in 2021, then plummeted 76.85% in 2024.
  • Ekso Bionics Holdings' Cash & Equivalents stood at $40.4 million in 2021, then plummeted by 49.2% to $20.5 million in 2022, then tumbled by 57.91% to $8.6 million in 2023, then tumbled by 76.85% to $2.0 million in 2024, then plummeted by 41.55% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Cash & Equivalents are $1.2 million (Q4 2025), $2.7 million (Q3 2025), and $5.2 million (Q2 2025).